American Heart Journal
Volume 150, Issue 4 , Pages 689.e11-689.e16 , October 2005

Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarction

Received 10 July 2004 ,Accepted 26 March 2005.

References 

  1. The SOLVD Investigators . Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:239–302
  2. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669–677
  3. Konstam MA, Kronenberg MW, Rousseauet MF, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation. 1993;88:2277–2283
  4. Falkenhahn M, Franke F, Bohle RM, et al. Cellular distribution of angiotensin-converting enzyme after myocardial infarction. Hypertension. 1995;25:219–226
  5. Hokimoto S, Yasue H, Fujimoto K, et al. Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction. Circulation. 1996;94:1513–1518
  6. Takai S, Shiota N, Kobayashi S, et al. Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett. 1997;412:86–90
  7. Akasu M, Urata H, Kinoshita A, et al. Differences in tissue angiotensin II–forming pathways by species and organs in vitro. Hypertension. 1998;32:514–520
  8. Cohn JN, Tognoni G, Valsartan heart failure trial investigators . A randomized trial of angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675
  9. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–766
  10. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582–1587
  11. Dickstein K, Kjekshus J, the OPTIMAAL Steering Committee . Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet. 2002;360:752–760
  12. Mukoyama M, Nakao K, Saito Y, et al. Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med. 1990;323:757–758
  13. Marijianowski MM, Teeling P, Becker AE. Remodeling after myocardial infarction in humans is not associated with interstitial fibrosis of noninfarcted myocardium. J Am Coll Cardiol. 1997;30:76–82
  14. Spinale FG, Coker ML, Krombach SR, et al. Matrix metalloproteinase inhibition during the development of congestive heart failure. Effects on left ventricular dimensions and function. Circ Res. 1999;85:364–376
  15. Rohde LE, Ducharme A, Arroyo LH, et al. Matrix metalloproteinases inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 1999;99:3063–3070
  16. Kameda K, Matsunaga T, Abe N, et al. Correlation of oxidative stress with the activity of matrix metalloproteinase in patients with coronary artery disease: possible role for left ventricular remodeling. Eur Heart J. 2003;24:2180–2185
  17. Lods N, Ferrari P, Frey FJ, et al. Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis. J Am Soc Nephrol. 2003;14:2861–2872
  18. Bruemmer D, Collins1 AR, Noh G, et al. Angiotensin II–accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest. 2003;112:1318–1331
  19. Wang M, Takagi G, Asai K, et al. Aging increases aortic MMP-2 activity and angiotensin II in nonhuman primates. Hypertension. 2003;41:1308–1316
  20. Kuga T, Mohri M, Egashira K, et al. Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin-converting enzyme. J Am Coll Cardiol. 1997;30:108–112
  21. Varin R, Mulder P, Tamion F, et al. Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: role of nitric oxide, prostanoids, oxidant stress, and bradykinin. Circulation. 2000;102:351–356
  22. Wang CH, Leung N, Lapointe N, et al. Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker. Circulation. 2003;107:1923–1929
  23. Maia LN, Nicolau JC, Vitola JV, et al. Prospective evaluation comparing the effects of enalapril and losartan in left ventricular remodeling after acute myocardial infarction. Am Heart J. 2003;145:e27
  24. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med. 1999;341:1949–1956
  25. Kramer CM, Rogers WJ, Theobald TM, et al. Dissociation between changes in intramyocardial function and left ventricular volumes in the eight weeks after first anterior myocardial infarction. J Am Coll Cardiol. 1997;30:1625–1632
  26. Matsumori A. ARCh-J study investigators. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail. 2003;5:669–677
  27. de Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415–472
  28. Fogari R, Mugellini A, Zoppi A, et al. A double-blind, crossover study of the antihypertensive efficacy of angiotensin II–receptor antagonists and their activation of the rennin-angiotensin system. Curr Ther Res Clin Exp. 2000;61:669–679
  29. Shricker K, Holmer S, Kramer BK, et al. The role of angiotensin II in the feedback control of renin gene expression. Pflugers Arch. 1997;434:166–172

PII: S0002-8703(05)00337-6

doi: 10.1016/j.ahj.2005.03.038

American Heart Journal
Volume 150, Issue 4 , Pages 689.e11-689.e16 , October 2005

Article Tools

* Image Usage & Resolution